検索結果

therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed to improve both subjective symptoms and objective signs of DED through inhibition ...

vative. BAC is widely used in eye drops but it is known to occasionally cause corneal epithelial damage1. Our goal was to develop a formulation that maintains the efficacy of the previous formulation ...

学会発表実績 | 研究開発活動 | 千寿製薬株式会社

寿製薬株式会社 もっと見る 海外 AAO 2025 開催日：2025年10月17日～2025年10月20日 開催地：Orlando, FL, USA Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double-Masked, Placebo-Controlled Phase 3 Piv...

quarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: To...

quarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: To...